

## **Expanded Materials and Methods**

### **Isolation of AT-derived SVCs and flow cytometry**

One gram of peri-epididymal fat from lean and obese C57BL/6J mice (15 weeks of LF or HF diet, respectively) was minced in PBS containing 2% bovine serum albumin (BSA) and 250 U/ml of collagenase type II (Worthington) and incubated at 37°C for 1 h. The digested tissue was passed through a 70- $\mu$ m cell strainer (BD Biosciences) and the flow-through centrifuged. After aspirating the supernatant, red blood cells were lysed with ACK lysing buffer (Gibco). The remaining cells were washed with DMEM supplemented with 10% FCS, counted and labeled with conjugated antibodies or their respective isotype controls before acquisition by a FACScan.

### **Analysis of inflammatory cells in AT by immunohistochemistry**

Peri-epididymal AT (from mice on LF or HF diet for 21 weeks) was fixed in periodate-lysine-paraformaldehyde fixative as described previously (see reference in the text), and embedded in paraffin. Five-micron sections were stained for rat anti-mouse CD45, Mac-3, I-A<sup>b</sup> (BD Pharmingen) and CD3 (Abcam), and then incubated with appropriate biotinylated secondary antibodies followed by incubation with avidin-biotin complex (Vector). Next, the reaction was visualized with 3-amino-9-ethyl carbazole (DAKO). Sections were counterstained with Gill's hematoxylin solution (Sigma). Positive cells were counted in 10 consecutive visual fields at the same magnification.

**Culture and differentiation of 3T3-L1 cells**

Murine 3T3-L1 pre-adipocytes were cultivated in DMEM high glucose supplemented with 10% FCS. After reaching confluency (day 0), cells were stimulated with DMEM containing 10% FCS, 0.5 mmol/L 3-Isobutyl-1-methylxanthine (Sigma), 1  $\mu$ mol/L dexamethasone (Sigma), and 10  $\mu$ g/ml of porcine insulin (Sigma), to induce differentiation. At day 2, media were replaced by DMEM with 10% FCS and 10  $\mu$ g/ml of insulin, and changed every 48 h. At day 11, cells were stimulated with recombinant mouse IFN $\gamma$  (Chemicon) at 10, 50, or 100 U/ml, and harvested 24 h after stimulation.

**Culture and activation of T cells *in vitro***

Splenic CD4<sup>+</sup> T cells were positively selected from C57BL/6J male mice and cultured *in vitro* with 2  $\mu$ g/ml of anti-CD28 (Bioexpress) and 10 ng/ml of recombinant mouse IL-12 (R&D Systems) in a plate coated with 5  $\mu$ g/ml of anti-CD3 (BD Pharmingen). After 48 h of incubation at 37°C, cells were transferred to fresh plates and incubated with 10 U/ml of recombinant mouse IL-2 (R&D Systems) for 72 h. Cells were then washed and again incubated in a plate coated with anti-CD3. After 48 h, conditioned media were used to stimulate differentiated 3T3-L1 cells for 24 h in the presence or absence of a neutralizing anti-IFN $\gamma$  antibody at 10  $\mu$ g/ml.

**Sequences of mouse primers**

TNF $\alpha$ , 5'-CTGTAGCCCACGTCGTAGC-3' and 5'-TTGAGATCCATGCCGTTG-3';  
 CD68, 5'-CTCTCTAAGGCTACAGGCTGCT-3' and 5'-  
 TCACGGTTGCAAGAGAAACA-3'; MCP-1, 5'-GGCTGGAGAGCTACAAGAGG-3'  
 and 5'-TCTTGAGCTTGGTGACAAAAAC-3'; RANTES, 5'-  
 AGCAGCAAGTGCTCCAATC-3' and 5'-GGGAAGCGTATACAGGGTC-3'; IL-10,  
 5'-ACTGCACCCACTTCCCAGT-3' and 5'-TGTCCAGCTGGTCCTTTGTT-3';  
 STAT-1, 5'-TGAGATGTCCCGGATAGTGG-3' and 5'-  
 CGCCAGAGAGAAATTCGTGT-3'; IFN $\gamma$ , 5'-TCTGGAGGAACTGGCAAAAG-3'  
 and 5'-TTCAAGACTTCAAAGAGTCTGAGG-3'; IP-10, 5'-  
 GCTGCCGTCATTTTCTGC-3' and 5'-TCTCACTGGCCCGTCATC-3'; MIG, 5'-  
 CTTTTCTTTTGGGCATCAT-3' and 5'-GCATCGTGCATTCCCTTATCA-3';  
 CXCR3, 5'-GCCAAGCCATGTACCTTGAG-3' and 5'-  
 GGAGAGGTGCTGTTTTCCAG-3'; I-A<sup>b</sup>, 5'-GTGGTGCTGATGGTGCTG-3' and  
 5'-CCATGAACTGGTACACGAAATG-3'; CD3, 5'-TCCCAACCCAGACTATGAGC-  
 3' and 5'-GCGATGTCTCTCCTATCTGTCA-3'; GAPDH, 5'-  
 TGGGTGTGAACCATGAGAAG-3' and 5'-GCTAAGCAGTTGGTGGTGC-3'.

**Supplementary figure 1. Plasma levels of adiponectin, leptin, and total cholesterol.**

Values representing the animals individually and the average in each group are plotted for each measurement. WT/LF, wild type mice/low fat diet; IFN $\gamma$ <sup>-/-</sup>LF, IFN $\gamma$ -deficient mice/low fat diet; WT/HF, wild type mice/high fat diet; IFN $\gamma$ <sup>-/-</sup>HF,

IFN $\gamma$ -deficient mice/high fat diet.  $\$p < 0.05$  relative to WT/LF; # $p < 0.05$ ; n=5-6 in each group.

**Supplementary figure 2. IFN $\gamma$  deficiency limits the number of crown-like formations in obese visceral AT.**

Peri-epididymal AT was fixed and paraffin-embedded. Sections were stained with anti-CD45 antibody, and “crowns” were counted in 10 consecutive fields in each slide. One crown is the result of positive cells around one single adipocyte. A representative picture from each group is shown (A-D). Numbers from each group were plotted in the graph (E). Differences were calculated by Student's t test. WT/LF, wild type mice/low fat diet; IFN $\gamma$ <sup>-/-</sup>LF, IFN $\gamma$ -deficient mice/low fat diet; WT/HF, wild type mice/high fat diet; IFN $\gamma$ <sup>-/-</sup>HF, IFN $\gamma$ -deficient mice/high fat diet; \* $p < 0.05$ ; n=5-6 in each group.


**Supplementary figure 3. Plasma levels of total cholesterol, triglycerides, and glucose in ApoE<sup>-/-</sup> and IFN $\gamma$ R<sup>-/-</sup>ApoE<sup>-/-</sup>**

Values representing the animals individually and the average in each group are plotted for each measurement. ApoE<sup>-/-</sup>, apolipoprotein E-deficient mice; IFN $\gamma$ R<sup>-/-</sup>ApoE<sup>-/-</sup>, IFN $\gamma$ -receptor-deficient and ApoE-deficient mice. \* $p < 0.01$  vs ApoE<sup>-/-</sup>; n=9 in each group.

## Supplementary table 1. Transcription profiling study

Differentiated 3T3-L1 cells were stimulated with 100 U/ml of recombinant mouse IFN $\gamma$  or left untreated (controls). After 4 and 24 h, control and treated cells were harvested and mRNA was extracted and used in a microarray screening. The table shows the CC and CXC chemokines and receptors that significantly changed compared to controls, ranked by their p value at 24h. n=5 for each group at 4 h, and n=6 for each group at 24 h.

| Gene                                  | Other denominations                   | 4h                 | 4h             | 24h                | 24h            |
|---------------------------------------|---------------------------------------|--------------------|----------------|--------------------|----------------|
|                                       |                                       | paired t statistic | paired p value | paired t statistic | paired p value |
| Chemokine (C-X-C motif) ligand 9      | Cxcl9, Mig                            | 5.159              | 0.006703       | 31.630             | 0.000001       |
| Chemokine (C-X-C motif) ligand 10     | Cxcl10, IP-10                         | 5.316              | 0.006020       | 20.312             | 0.000005       |
| Chemokine (C-C motif) ligand 5        | Ccl5, RANTES                          | 4.797              | 0.008668       | 16.707             | 0.000014       |
| Chemokine (C-C motif) ligand 8        | Ccl8, MCP-2                           | 9.577              | 0.000664       | 16.511             | 0.000015       |
| Chemokine (C-X-C motif) ligand 11     | Cxcl11, I-TAC                         | 3.984              | 0.016351       | 8.116              | 0.000461       |
| Chemokine (C-C motif) ligand 2        | Ccl2, MCP-1                           | 3.645              | 0.021865       | 6.508              | 0.001279       |
| Chemokine (C-C motif) ligand 7        | Ccl7, MCP-3                           | 3.851              | 0.018286       | 5.907              | 0.001980       |
| Chemokine (C-X-C motif) ligand 13     | Cxcl13, BLC, BCA-1                    | 4.013              | 0.015961       | 5.281              | 0.003243       |
| Chemokine (C-C motif) receptor-like 1 | Ccr1                                  | 0.195              | NS             | 5.151              | 0.003613       |
| Chemokine (C-X-C motif) ligand 2      | Cxcl2, GRO- $\beta$ , MGSA- $\beta$   | 12.422             | NS             | 4.976              | 0.004190       |
| Chemokine (C-X-C motif) ligand 12     | Cxcl12, SDF-1 $\alpha/\beta$          | 14.831             | NS             | 4.007              | 0.010249       |
| Chemokine (C-X-C motif) receptor 3    | Cxcr3                                 | 14.784             | NS             | 3.999              | 0.010336       |
| Chemokine (C-C motif) ligand 25       | Ccl25, TECK                           | 3.378              | 0.027842       | 3.934              | 0.011023       |
| Chemokine (C-X-C motif) ligand 16     | Cxcl16                                | 3.317              | 0.029452       | 3.858              | 0.011907       |
| Chemokine (C-X-C motif) ligand 7      | Cxcl7, NAP-2                          | 0.515              | NS             | 3.734              | 0.013510       |
| Chemokine (C-C motif) receptor 1      | Ccr1                                  | 2.744              | NS             | 3.619              | 0.015239       |
| Chemokine (C-X-C motif) ligand 1      | Cxcl1, GRO- $\alpha$ , MGSA- $\alpha$ | 14.008             | NS             | 3.403              | 0.019192       |
| Chemokine (C-X-C motif) ligand 15     | Cxcl15                                | 1.027              | NS             | 3.016              | 0.029567       |
| Chemokine (C-C motif) ligand 28       | Ccl28, MEC                            | 27.063             | NS             | 2.771              | 0.039325       |
| Chemokine (C-C Motif) Ligand 12       | Ccl12                                 | 8.944              | 0.000864       | 22.227             | NS             |
| Chemokine (C-X3-C Motif) Ligand 1     | Cx3cl1, Fractalkine                   | 6.665              | 0.002632       | 11.542             | NS             |
| Chemokine (C-C Motif) Ligand 4        | Ccl4, MIP-1 $\beta$                   | 4.243              | 0.013233       | 12.488             | NS             |
| Chemokine (C-X3-C) receptor 1         | Cx3cr1                                | 3.384              | 0.027684       | 10.979             | NS             |



Supplementary figure 2

